论文部分内容阅读
目的探讨glypican-3、Hep Par1和CD34在肝细胞癌(HCC)中的表达及临床意义。方法通过免疫组化方法研究101例肝细胞癌及癌旁组织中glypican-3、Hep Par1和CD34的表达情况,探讨其在肝细胞癌诊断中的意义,并分析其与临床病理特征的关系。结果在HCC中glypican-3阳性率为83.2%,在癌旁正常肝组织内为(-)。在HCC中Hep Par1阳性率为90.1%。glypican-3和Hep Par1的表达与肿瘤分化程度相关(P<0.05),而与患者年龄、性别、微血管浸润、有/无肝硬化均无明显相关性(P>0.05)。CD34呈现特殊的HCC型微血管染色。结论glypican-3、Hep Par1和CD34联合使用对HCC的诊断有更显著的敏感性及特异性,建议作为HCC诊断的首选一线抗体。
Objective To investigate the expression and clinical significance of glypican-3, Hep Par1 and CD34 in hepatocellular carcinoma (HCC). Methods The expression of glypican-3, Hep Par1 and CD34 in 101 cases of hepatocellular carcinoma and adjacent non-cancerous tissues was studied by immunohistochemistry. The significance of glypican-3, Hep Par1 and CD34 in hepatocellular carcinoma was analyzed and their relationship with clinicopathological features was analyzed. Results The positive rate of glypican-3 in HCC was 83.2%, and it was (-) in normal liver adjacent tissues. The positive rate of Hep Par1 in HCC was 90.1%. The expression of glypican-3 and Hep Par1 correlated with the degree of tumor differentiation (P <0.05), but not with age, gender, microvascular invasion, and / or cirrhosis (P> 0.05). CD34 presents a special type of HCC microvascular staining. Conclusion The combined use of glypican-3, Hep Par1 and CD34 has a more significant sensitivity and specificity for the diagnosis of HCC, and is recommended as the first-line antibody for the diagnosis of HCC.